Sutro Biopharma's Ovarian Cancer Candidate Fast Tracked In US

by Vandana Singh, Benzinga Editor

August 18, 2021 8:05 AM | 1 min read |

The FDA has granted Fast Track designation to Sutro Biopharma Inc's STRO STRO-002 for ovarian cancer.
The designation covers platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients who have received one to three prior lines of systemic therapy.
STRO-001-GM1 is a Phase 1 trial for STRO-002 for patients with advanced ovarian cancer that have progressed or relapsed after standard of care treatments to assess efficacy, safety, and tolerability.
STRO-002, a folate receptor alpha (FolRα)-targeting antibody-drug conjugate.
Related content: Benzinga's Full FDA Calendar.
Price Action: STRO shares are up 4.09% at $19.60 during the premarket session on the last check Wednesday.

Posted In: Biotech News Health Care Small Cap FDA Movers Trading Ideas General Briefs Fast Track Designation Ovarian Cancer Phase 1 Trial

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.